Bayer HealthCare commences phase III liver cancer drug trial

Bayer HealthCare has announced the commencement of Resorce, a phase III clinical trial assessing its drug regorafenib in the treatment of advanced liver cancer.

Patient enrolment has now begun for the international study, which aims to evaluate the efficacy and safety of regorafenib for the treatment of patients with hepatocellular carcinoma who have progressed on sorafenib treatment.

Approximately 530 subjects will be enrolled for the trial, which will be conducted in North America, South America, Europe, Asia and Australia.

This ties in with Bayer's ongoing commitment to developing novel therapy options for patients affected by difficult-to-treat forms of cancer.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "There is a high unmet medical need for patients with advanced liver cancer whose disease has progressed after treatment with sorafenib."

Last month, the company presented new data on a number of cancer therapies – including Mesothelin-ADC, BAY 80-6946 and refametinib – at the American Association for Cancer Research annual meeting.